依西美坦-话题@MedSci

#依西美坦#

8篇内容 | 689人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1655175, encodeId=623a16551e5f2, content=<a href='/topic/show?id=9b362692674' target=_blank style='color:#2F92EE;'>#依西美坦#</a>, objectTitle=J Clin Oncol：依西美坦和恩替诺他联合治疗AI耐药的HR阳性、HER2阴性晚期乳腺癌, objectType=article, longId=215465, objectId=b32a2154654f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b32a2154654f, replyNumber=0, likeNumber=34, createdTime=2021-08-22, rootId=0, userName=fzwish20008, userId=61b724663185, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b32a2154654f, moduleTitle=J Clin Oncol：依西美坦和恩替诺他联合治疗AI耐药的HR阳性、HER2阴性晚期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b32a2154654f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1655174, encodeId=3ddd16551e42a, content=<a href='/topic/show?id=9b362692674' target=_blank style='color:#2F92EE;'>#依西美坦#</a>, objectTitle=Clin Cancer Res:瑞博西尼（ribociclib）联合依西美坦+依维莫司治疗CDK4/6抑制剂治疗进展的HR+/HER2-晚期乳腺癌的疗效和安全性：I/II期TRINITI-1研究, objectType=article, longId=213367, objectId=676e21336e25, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=676e21336e25, replyNumber=0, likeNumber=54, createdTime=2022-03-02, rootId=0, userName=fzwish20008, userId=61b724663185, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=676e21336e25, moduleTitle=Clin Cancer Res:瑞博西尼（ribociclib）联合依西美坦+依维莫司治疗CDK4/6抑制剂治疗进展的HR+/HER2-晚期乳腺癌的疗效和安全性：I/II期TRINITI-1研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=676e21336e25)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1655173, encodeId=d7ee16551e35e, content=<a href='/topic/show?id=9b362692674' target=_blank style='color:#2F92EE;'>#依西美坦#</a>, objectTitle=Lancet Oncol：Tucidinostat联合依西美坦治疗激素受体阳性晚期乳腺癌, objectType=article, longId=165129, objectId=96ad1651296c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96ad1651296c, replyNumber=0, likeNumber=53, createdTime=2019-06-21, rootId=0, userName=fzwish20008, userId=61b724663185, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96ad1651296c, moduleTitle=Lancet Oncol：Tucidinostat联合依西美坦治疗激素受体阳性晚期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96ad1651296c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1655172, encodeId=34d516551e2a9, content=<a href='/topic/show?id=9b362692674' target=_blank style='color:#2F92EE;'>#依西美坦#</a>, objectTitle=Lancet Oncol：绝经后妇女早期乳腺癌辅助化疗：他莫昔芬+依西美坦vs依西美坦, objectType=article, longId=113199, objectId=989711319916, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=989711319916, replyNumber=0, likeNumber=38, createdTime=2017-09-27, rootId=0, userName=fzwish20008, userId=61b724663185, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=989711319916, moduleTitle=Lancet Oncol：绝经后妇女早期乳腺癌辅助化疗：他莫昔芬+依西美坦vs依西美坦, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=989711319916)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1655171, encodeId=8c8216551e119, content=<a href='/topic/show?id=9b362692674' target=_blank style='color:#2F92EE;'>#依西美坦#</a>, objectTitle=招募患者：西达本胺联合依西美坦治疗激素受体阳性晚期乳腺癌的III期临床试验, objectType=article, longId=56014, objectId=262d56014f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=262d56014f0, replyNumber=0, likeNumber=30, createdTime=2016-01-16, rootId=0, userName=fzwish20008, userId=61b724663185, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=262d56014f0, moduleTitle=招募患者：西达本胺联合依西美坦治疗激素受体阳性晚期乳腺癌的III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=262d56014f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1655170, encodeId=318816551e068, content=<a href='/topic/show?id=9b362692674' target=_blank style='color:#2F92EE;'>#依西美坦#</a>, objectTitle=Lancet：依西美坦和他莫昔芬治疗女性绝经前早期乳腺癌并接受卵巢抑制的疗效, objectType=article, longId=52349, objectId=328f52349b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=328f52349b9, replyNumber=0, likeNumber=36, createdTime=2015-12-28, rootId=0, userName=fzwish20008, userId=61b724663185, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=328f52349b9, moduleTitle=Lancet：依西美坦和他莫昔芬治疗女性绝经前早期乳腺癌并接受卵巢抑制的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=328f52349b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1655169, encodeId=21f016551693e, content=<a href='/topic/show?id=9b362692674' target=_blank style='color:#2F92EE;'>#依西美坦#</a>, objectTitle=NEJM：依西美坦或为年轻乳腺癌患者的新选择, objectType=article, longId=46030, objectId=0f544603027, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f544603027, replyNumber=0, likeNumber=53, createdTime=2015-04-13, rootId=0, userName=fzwish20008, userId=61b724663185, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f544603027, moduleTitle=NEJM：依西美坦或为年轻乳腺癌患者的新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f544603027)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1655168, encodeId=5996165516814, content=<a href='/topic/show?id=9b362692674' target=_blank style='color:#2F92EE;'>#依西美坦#</a>, objectTitle=ASCO 2014：依西美坦与他莫西芬治疗绝经前HR+乳腺癌疗效比较（TEXT和SOFT研究）, objectType=article, longId=35751, objectId=96ee35e5103, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96ee35e5103, replyNumber=0, likeNumber=0, createdTime=2015-01-14, rootId=0, userName=fzwish20008, userId=61b724663185, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96ee35e5103, moduleTitle=ASCO 2014：依西美坦与他莫西芬治疗绝经前HR+乳腺癌疗效比较（TEXT和SOFT研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96ee35e5103)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

依西美坦

2020-05-29

fzwish20008 (审核中...)

前往app查看评论内容

#依西美坦#

J Clin Oncol：依西美坦和恩替诺他联合治疗AI耐药的HR阳性、HER2阴性晚期乳腺癌

2021-08-22

fzwish20008 (审核中...)

前往app查看评论内容

#依西美坦#

Clin Cancer Res:瑞博西尼（ribociclib）联合依西美坦+依维莫司治疗CDK4/6抑制剂治疗进展的HR+/HER2-晚期乳腺癌的疗效和安全性：I/II期TRINITI-1研究

2022-03-02

fzwish20008 (审核中...)

前往app查看评论内容

#依西美坦#

Lancet Oncol：Tucidinostat联合依西美坦治疗激素受体阳性晚期乳腺癌

2019-06-21

fzwish20008 (审核中...)

前往app查看评论内容

#依西美坦#

Lancet Oncol：绝经后妇女早期乳腺癌辅助化疗：他莫昔芬+依西美坦vs依西美坦

2017-09-27

fzwish20008 (审核中...)

前往app查看评论内容

#依西美坦#

招募患者：西达本胺联合依西美坦治疗激素受体阳性晚期乳腺癌的III期临床试验

2016-01-16

fzwish20008 (审核中...)

前往app查看评论内容

#依西美坦#

Lancet：依西美坦和他莫昔芬治疗女性绝经前早期乳腺癌并接受卵巢抑制的疗效

2015-12-28

fzwish20008 (审核中...)

前往app查看评论内容

#依西美坦#

NEJM：依西美坦或为年轻乳腺癌患者的新选择

2015-04-13

fzwish20008 (审核中...)

前往app查看评论内容

#依西美坦#

ASCO 2014：依西美坦与他莫西芬治疗绝经前HR+乳腺癌疗效比较（TEXT和SOFT研究）

2015-01-14

科室
- - 订阅+
  - 更多科室
工具
服务